South San Francisco, CA Breaking News Headlines Today

News about South San Francisco

Stay current with all the latest and breaking news about South San Francisco, compare headlines and perspectives between news sources on stories happening today. In total, 150 stories have been published about South San Francisco which Ground News has aggregated in the past 3 months.

Local News Publishers

Untracked bias

Suggest a source

Looking for a source we don't already have? Suggest one here.

Top South San Francisco News

South San Francisco · South San Francisco

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

100% Center coverage: 2 sources

See the Story

South San Francisco · South San Francisco

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

100% Center coverage: 2 sources

South San Francisco · South San Francisco See the Story

Star Therapeutics Receives FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VGA039 in Von Willebrand Disease Prophylaxis

South San Francisco · South San Francisco Read Article

BVB | Gaels Head to Santa Monica as Three Seed in WCC Tournament

South San Francisco · South San Francisco See the Story

AAN 2026 The First BTK inhibitor for PPMS to Make-It?

South San Francisco · South San Francisco Read Article

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000

100% Left coverage: 1 sources

CFO · South San Francisco Read Article

Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026

South San Francisco · South San Francisco Read Article

Goldman Sachs Lists 19-Acre Southline Phase 2 Development Site for Sale in South San Francisco

BART · South San Francisco Read Article

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

100% Center coverage: 1 sources

South San Francisco · South San Francisco Read Article

ADM to Release First Quarter Financial Results on May 5, 2026

44% Left coverage: 9 sources

Business · Burnaby See the Story

News about South San Francisco

News about South San Francisco

Local News Publishers Too Big Arrow Icon

Top South San Francisco News

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

Maze Therapeutics Announces $150 Million Registered Offering

BVB | Gaels Head to Santa Monica as Three Seed in WCC Tournament

Maze Therapeutics Announces $150 Million Registered Offering

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

Star Therapeutics Receives FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VGA039 in Von Willebrand Disease Prophylaxis

BVB | Gaels Head to Santa Monica as Three Seed in WCC Tournament

AAN 2026 The First BTK inhibitor for PPMS to Make-It?

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000

Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026

Goldman Sachs Lists 19-Acre Southline Phase 2 Development Site for Sale in South San Francisco

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

ADM to Release First Quarter Financial Results on May 5, 2026

Local News Publishers Too Big Arrow Icon

Breaking News Topics Related to South San Francisco

Maze Therapeutics Announces $150 Million Registered Offering

Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS

Star Therapeutics Receives FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VGA039 in Von Willebrand Disease Prophylaxis

BVB | Gaels Head to Santa Monica as Three Seed in WCC Tournament

AAN 2026 The First BTK inhibitor for PPMS to Make-It?

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000

Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026

Goldman Sachs Lists 19-Acre Southline Phase 2 Development Site for Sale in South San Francisco

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

ADM to Release First Quarter Financial Results on May 5, 2026

Local News Publishers

Local News Publishers